TRVI
Trevi Therapeutics, Inc.Healthcare · $2.0B market cap
Verdict
We can't put a fair value on TRVI right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow TRVI
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds TRVI. In Q2 2026, 1 trimmed. Who we track
Moves in Q2 2026
Trimmed: Viking Global Investors
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works